Bio1 Clinical Research Inc — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2021	Research	$2,000	1
2020	Research	$20,578	3
2019	Research	$33,879	5

Breakdown

Who paid Research payments · program years 2019–2021

Boehringer Ingelheim Pharmaceuticals, Inc. $34,644 3 payments
Dr.Reddy's Laboratories,Inc. $9,000 3 payments
Amarin Pharma Inc. $6,485 1 payment
Akcea Therapeutics, Inc. $6,328 2 payments

Studies the money was for Research payments · program years 2019–2021

Exercise capacity study in HFpEF $18,878 2 payments
Exercise capacity study in HFrEF $15,765 1 payment
A Phase 3 randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan or MabThera $9,000 3 payments
A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardio $6,485 1 payment
Isis 678354-Cs2 $6,328 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.